Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
Fibrodysplasia ossificans progressiva (FOP), a rare genetic and catastrophic disorder characterized by progressive heterotopic ossification, is caused by a point mutation, c.617G>A; p.R206H, in the activin A receptor type 1 (ACVR1) gene, one of the bone morphogenetic protein type I receptors (BMPR-Is). Although altered BMP signaling has been suggested to explain the pathogenesis, the molecular consequences of this mutation are still elusive. Here we studied the impact of ACVR1 R206H mutation on BMP signaling and its downstream signaling cascades in murine myogenic C2C12 cells and HEK 293 cells. We found that ACVR1 was the most abundant of the BMPR-Is expressed in mesenchymal cells but its contribution to osteogenic BMP signal transduction was minor. The R206H mutant caused weak activation of the BMP signaling pathway, unlike the Q207D mutant, a strong and constitutively active form. The R206H mutant showed a decreased binding affinity for FKBP1A/FKBP12, a known safeguard molecule against the leakage of transforming growth factor (TGF)-beta or BMP signaling. The decreased binding affinity of FKBP1A to the mutant R206H ACVR1 resulted in leaky activation of the BMP signal, and moreover, it decreased steady-state R206H ACVR1 protein levels. Interestingly, while WT ACVR1 and FKBP1A were broadly distributed in plasma membrane and cytoplasm without BMP-2 stimulation and then localized in plasma membrane on BMP-2 stimulation, R206H ACVR1 and FKBP1A were mainly distributed in plasma membrane regardless of BMP-2 stimulation. The impaired binding to FKBP1A and an altered subcellular distribution by R206H ACVR1 mutation may result in mild activation of osteogenic BMP-signaling in extraskeletal sites such as muscle, which eventually lead to delayed and progressive ectopic bone formation in FOP patients.
Song
Gin-Ah
GA
Department of Molecular Genetics, BK21 Program, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 110-749, Korea.
Kim
Hyun-Jung
HJ
Woo
Kyung-Mi
KM
Baek
Jeong-Hwa
JH
Kim
Gwan-Shik
GS
Choi
Jin-Young
JY
Ryoo
Hyun-Mo
HM
D030201:Activin Receptors, Type I / Q000235:genetics* / Q000378:metabolism; D019943:Amino Acid Substitution / Q000235:genetics*; D000818:Animals; D052005:Bone Morphogenetic Protein Receptors, Type I / Q000235:genetics; D002460:Cell Line; D005786:Gene Expression Regulation; D051379:Mice; D050505:Mutant Proteins / Q000378:metabolism; D009154:Mutation / Q000235:genetics*; D009221:Myositis Ossificans / Q000235:genetics*; D010012:Osteogenesis; D011485:Protein Binding; D055550:Protein Stability; D015398:Signal Transduction; D013347:Subcellular Fractions / Q000378:metabolism; D022061:Tacrolimus Binding Protein 1A / Q000378:metabolism
D050505:Mutant Proteins; C425423:ACVR1 protein, human; D030201:Activin Receptors, Type I; C498943:Acvr1 protein, mouse; D052005:Bone Morphogenetic Protein Receptors, Type I; D022061:Tacrolimus Binding Protein 1A
Mol Cell Biol. 1995 Jul;15(7):3479-86
7791754
Mol Cell Biol. 2000 Dec;20(23):8783-92
11073979
Am J Pathol. 2007 Feb;170(2):620-32
17255330
J Biol Chem. 2009 Mar 13;284(11):7149-56
18684712
Hum Mol Genet. 2005 Jan 15;14(2):295-305
15574464
Bone. 2008 Sep;43(3):427-33
18590993
Nat Genet. 2006 May;38(5):525-7
16642017
Circulation. 2009 Jun 23;119(24):3062-9
19506109
Biochemistry. 1998 Nov 17;37(46):16360-8
9819228
FEBS Lett. 2001 Apr 20;495(1-2):1-6
11322937
Nature. 2003 Oct 9;425(6958):577-84
14534577
J Biol Chem. 2004 Dec 3;279(49):50773-80
15383550
Mol Cell Biol. 2006 Oct;26(20):7791-805
16923969
EMBO J. 1995 May 15;14(10):2199-208
7774578
Annu Rev Biochem. 1998;67:199-225
9759488
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2425-30
11226255
Cell. 1995 Oct 6;83(1):129-35
7553864
J Bone Miner Res. 2010 Jun;25(6):1208-15
19929436
Hum Reprod. 2009 Jan;24(1):241-9
18854405
Pediatrics. 2008 May;121(5):e1295-300
18450872
Cell. 1996 Aug 9;86(3):435-44
8756725
J Cell Sci. 2005 Dec 1;118(Pt 23):5443-51
16278292
J Inherit Metab Dis. 2000 Jul;23(5):441-7
10947197
J Cell Sci. 2005 Feb 1;118(Pt 3):643-50
15657086
J Immunol. 1989 Sep 1;143(5):1580-3
2474605
Cell. 1994 May 20;77(4):513-23
7514503
N Engl J Med. 1996 Aug 22;335(8):555-61
8678932
EMBO J. 1997 Jul 1;16(13):3866-76
9233797
Curr Opin Genet Dev. 1996 Aug;6(4):432-8
8791534
J Biol Chem. 2008 Jul 25;283(30):20948-58
18436533
J Bone Joint Surg Am. 1993 Feb;75(2):215-9
8423182
Science. 2001 Mar 23;291(5512):2364-9
11269317
Nat Med. 2008 Dec;14(12):1363-9
19029982
Dev Biol. 2004 Dec 1;276(1):185-93
15531373
Nat Neurosci. 2005 Aug;8(8):1051-8
16025111
J Biol Chem. 2008 Nov 21;283(47):32751-61
18786927
J Biol Chem. 2003 Sep 5;278(36):34387-94
12815054
J Bone Miner Res. 2008 Mar;23(3):305-13
17967130
J Endocrinol. 2007 Oct;195(1):95-103
17911401
J Med Genet. 1993 Aug;30(8):687-9
8411056
Genes Dev. 2004 Aug 1;18(15):1838-49
15289457
Development. 1999 Sep;126(17):3795-809
10433909
J Biol Chem. 1996 Aug 23;271(34):20385-91
8702774
Int Rev Cytol. 2006;252:1-69
16984815
Cell. 1999 Feb 5;96(3):425-36
10025408
J Biol Chem. 2000 Apr 28;275(17):13149-54
10777621
J Bone Miner Res. 2005 Jul;20(7):1168-76
15940369
J Bone Joint Surg Br. 1982;64(1):76-83
7068725
Traffic. 2000 Nov;1(11):836-51
11208074
J Cell Biochem. 2006 Dec 1;99(5):1233-9
16795049
Development. 1999 Jun;126(11):2551-61
10226013
J Clin Invest. 2009 Nov;119(11):3462-72
19855136
Curr Opin Cell Biol. 2002 Aug;14(4):476-82
12383799
Mol Cell Biol. 1994 Sep;14(9):5961-74
8065329
New Biol. 1992 May;4(5):448-60
1515410
J Mol Endocrinol. 2006 Jun;36(3):569-79
16720724
Hum Mol Genet. 2003 Apr 1;12(7):727-37
12651868
FASEB J. 2010 Feb;24(2):357-63
19805579
Development. 2004 Jul;131(14):3481-90
15226263
Pediatrics. 2005 Nov;116(5):e654-61
16230464
Hum Mutat. 2009 Mar;30(3):379-90
19085907
FASEB J. 1994 Apr 1;8(6):391-400
7513288
Gene. 2006 Jan 17;366(1):51-7
16314053
Hum Mol Genet. 2005 Sep 1;14(17):2559-69
16049033
Nat Rev Mol Cell Biol. 2001 Oct;2(10):721-30
11584299
J Biol Chem. 2009 Sep 11;284(37):25230-40
19617624
Mol Endocrinol. 1997 Oct;11(11):1681-94
9328350